Status:
COMPLETED
Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Varian Medical Systems
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
AML is the most common leukemia diagnosed in adults. In spite of recent low-intensity therapies that have improved outcomes for older AML patients, AML remains associated with poor prognosis as well a...
Eligibility Criteria
Inclusion
- Patients being treated for a diagnosis of acute myeloid leukemia at Stanford Cancer Center
- Patients determined to be candidates for low intensity induction therapy (not requiring hospitalization to administer treatment) by their leukemia physician
- Estimated life expectancy of 6 months
- Functional status at the level of at least being capable of limited self-care, confined to chair or bed for half the day or better
- Access to smartphone, tablet, or computer with capability to utilize a symptom tracking application
Exclusion
- Relapsed or refractory AML
- Patients who have established care with palliative care previously
- Non-English-speaking, as the Noona application is developed in the English language
Key Trial Info
Start Date :
March 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04885127
Start Date
March 30 2022
End Date
September 30 2024
Last Update
June 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Palo Alto, California, United States, 94304